

Curidium Medica plc
("Curidium" or the "Company")

CURIDIUM CLOSES ON £2.5 MILLION FINANCING

- New funding to accelerate Company's Growth Strategy -

London, UK, 30 July, 2007, Curidium Medica plc, (LSE: CUR) today announced that it has placed 100,000,000 0.1 pence ordinary shares with strategic investors at a price of 2.5 pence per share resulting in gross proceeds of £2,500,000 to the Company.

The proceeds of the placing will be used to expand the Company's business and product development activities including the opportunities that have come with the recent discovery of Curidium's proprietary PsychINDx test.

"I am very pleased with the new investment in the Company" said Gosse B. Bruinsma MD, Executive Chairman of Curidium, "This financing reflects continued confidence in Curidium's platform and management and will help accelerate the Company's development in the personalized medicine space over the near term."

The new shares will be admitted to trading on AIM on 1 August 2007. Following this transaction the Company will have 557,811,392 ordinary shares in issue. As part of the transaction, the lead investor will also receive options to buy 5,000,000 ordinary shares at 2.5 pence exercisable during the next 5 years.

For further information please contact:

Gosse Bruinsma +44 (0) 20 7554 8790
Chairman, Curidium Medica plc

Rob Smith +44 (0) 20 7554 8793
Finance Director, Curidium Medica plc

Rhodri Cruwys / Romil Patel +44 (0) 20 7448 4400
Blue Oar Securities Plc

Billy Clegg / Edward Westropp / Anna Keeble + 44 (0)20 7831 3113
Financial Dynamics

Notes to Editors

Curidium Medica

Curidium is a personalized medicine company identifying targeted medicines and companion diagnostics to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has resulted in the

identification of a blood diagnostic test, PsychINDx™, which classifies patients with schizophrenia/bipolar disorder into four subgroups. PsychINDx™ may have the potential to improve the treatment of schizophrenic/bipolar disorder patients and may support the development of new drug treatments targeted for the different patient subgroups.

Many chronic human diseases are heterogeneous and their patient populations consist of mixed subgroups. Through the use of its proprietary analysis tool, Homomatrix®, Curidium aims to reveal different patient subgroups characterized by distinct underlying disease mechanisms potentially leading to the identification of:

- 1) Diagnostics for better identification and treatment within heterogeneous disease populations,
- 2) Improved therapies identified through novel drug targets
- 3) Personalized medicines using Companion Diagnostics and targeted treatments.

Curidium aims to continue to use this approach to improve patient treatments in a variety of therapeutic areas.

Further information on Curidium can be found at the Company's website: www.curidium.com.

Curidium Medica plc © 2002-2007. All rights reserved.

Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom.

Email: info@curidium.com Tel.: +44 (0)20 7554 8790, Fax: +44 (0)20 7554 8791